Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Bullboard Posts
Comment by longondmxon Jul 11, 2006 9:06am
149 Views
Post# 11086632

RE: NR - DEAL Sperm Sexing Technology

RE: NR - DEAL Sperm Sexing Technology Is it me, or is this news release huge?? Interested to see market reaction. I think this is going to be big. And a nice steady income stream to support any ongoing inititaives, and then some. If my math is right.... Sales so far are to 13% of all sperm sexing companies with expected sales of $350MM by 2010. MBX receives a MINIMUM of 15% of these sales, so that equates to $52 Million per year. Gastles expects 80% of all companies will sign on in 2 years. Assuming the same amount of sales per company...that would mean..... 80/13*52MM = $320 MILLION per YEAR in royalties. Someone care to confirm/dispute my logic??
Bullboard Posts